1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grants2025 Seed Grants is sponsored by University of Houston Drug Discovery Institute. Supports innovative drug discovery and development research through seed grants.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
The purpose of the UH Drug Discovery Institute seed grant program is to catalyze multidisciplinary research teams with seed funds that would facilitate preparation and submission of competitive extramural drug discovery and development research proposals. Full Guidelines Application Form Applications for the DDI Seed Grant Program are closed for 2026.
Catalyzing Novel Research It is expected that data from funded seed grants will be used to support strong federal or state grant applications. Applicants should include a plan and timeline for external grant submission (see Reporting Requirements below). Subsequent applications should represent a substantial return on investment, with all the planned submissions through the Drug Discovery Institute.
Scientific Track: $50,000 A Novel Closed-System Microfluidic Platform for High-Purity Lymphocyte Isolation from Whole Blood: Enhancing PSMA-Targeted CAR T Therapy for Prostate Cancer Team: Sergey Shevkoplyas, Cullen College of Engineering ; Qin Feng, College of Natural Sciences and Mathematics Mechanistically Novel Inhibitors of Androgen Receptor to Treat Prostate Team: Alexander V.
Statsyuk, College of Pharmacy ;Tasneem Bawa-Khalfe, College of Natural Sciences and Mathematics Studies on the Mycobactericidal Properties of Lysates from an Actinobacterial Isolate Tersicoccus Phoenicis Team: William Widger and Madhan Tirumalai, College of Natural Sciences and Mathematics; Patrick Cirino, Cullen College of Engineering Technique Expansion Track: $15,000 Improving CAR T Therapy Efficacy and Persistence through Modulation of a Transcriptional Coactivator PI: Qin Feng, College of Natural Sciences and Mathematics Novel Targeted Therapy for Vasculopathy in Cryopyrin-associated Periodic Syndrome PI: Yunting Wang, College of Pharmacy Electrochemical Method to Generate Gradient-Based High Throughput Screening Assay Al-Driven Scoring for Virtual Screening of Peptide-Based Ligands Brain Permeable PI3K Isoform Specific Inhibitor for Brain Metastases Co-PI: Weiyi Peng (Center for Nuclear Receptors & Cell Signaling) CRISPR-edited CAR NK Cells for Advanced Prostate Cancer Co-PI: Xinli Liu (Pharmacy) Novel Micropatterned Substrates for Cell Motility in 3D Aggregates of Ovarian Cancer PI: Tasneem Bawa-Khalfe (NSM) Co-PI: Fatima Merchant (Engineering Technology) Targeting ADGRF1 (GPR110) in HER2+ breast cancer PI: Meghana Trivedi (Pharmacy) Co-PI: Tasneem Bawa-Khalfe (NSM) Discovery of a novel inhibitor of IL-15 receptor for treatment of rheumatoid arthritis Co-PI: Gomika Udugamasooriya (Pharmacy) Co-PI: Chandra Mohan (Engineering) Novel Targeted Therapy for Hepatocellular Carcinoma
According to the current listing, eligibility includes: Research teams at the University of Houston. Confirm the full requirements in the official notice before applying.
2025 Seed Grants is funded by University of Houston Drug Discovery Institute. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
DARPA's DIAL program already had AI rediscover the Kalman filter and wavelets from scratch. SPEED DIAL (DPA26TZ05-DV003) funds the unglamorous next step: turning algorithm discovery into a tool that plugs into MATLAB, Simulink, and COMSOL. Up to $750,000 base plus a $1.25 million option, Direct to Phase II only, with a three-accomplishment feasibility gate and a mandatory university partner. Here is the milestone schedule, the interpretability requirement, and who is actually eligible.
Read articleThe HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleThe full ASPECT NOFO (DE-FOA-0003647) posted September 4, 2026, eleven days later than the Notice of Intent predicted. The real document splits $58 million across two topic areas with anticipated award counts of 0-7 and 0-3, a cost share that jumps from 20 percent to 50 percent mid-project, a mandatory five-page concept paper due October 9, and a university eligibility restriction that decides team structure before anyone writes a word.
Read article